A better understanding of the penetrance and the cost-effectiveness of TP53 p.Arg337His testing in women with pre-menopausal breast cancer regardless of family history criteria could contribute to determine if such testing is justified from a public health care perspective. This evidence concerns the gene TP53 and breast cancer.